Authors
W Alkhaffaf, M Alkataan
Published in
Georgian medical news. Issue 376-377. Pages 381-388.
Abstract
Migraine is a common neurological condition; it can be classed as episodic or chronic. In chronic migraine (CM), one of therapies have been revealed efficacy is onabotulinumtoxin A (OnaBT-A).
To confirm that the effect of OnaBT-A treatment is dose dependent for the treatment of CM Material and methods: This prospective, randomized, comparative study was carried out at a private neurological clinic in Mosul, Iraq. This study comprised a total of 106 patients who met the diagnostic criteria for CM. Two groups of patients were formed. The first group received 200 U of OnaBT-A by local injection, the second group received 155 U. Each group received OnaBT-A at the start of the trial, as well as after 12 weeks. The outcome indicators which include: monthly headache frequency, attack severity, duration of headaches, and disability, were collected and recorded at the baseline, at week 12 and at week 24.
All headache outcome variables showed significant improvement with both treatment regimens. The efficacy of these treatment approaches is confirmed by the statistically significant p-values' consistency across both groups. The most significant gains were seen in the 1st group with the higher dose.
The study concludes that administering 200 U of OnaBT-A, significantly decreases the frequency and duration of headaches when compared to 155 U. It recommends considering this dosage for patients who do not accomplish adequate relief with 155 U of OnaBT-A. The promising outcomes suggest a need for further studies into long-term effects and evaluation of higher dosages.
PMID:
42830078
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0